|
GOG3069: Phase 2 study of alpelisib and fulvestrant for PIK3CA-mutated estrogen receptor (ER)-positive endometrioid endometrial cancers. |
| |
|
Consulting or Advisory Role - Immunogen; Merck; Verastem |
Research Funding - AstraZeneca (Inst); Blueprint Pharmaceutic (Inst); Clovis Oncology (Inst); Compugen (Inst); Genentech/Roche (Inst); Immunogen (Inst); Iovance Biotherapeutics (Inst); Pfizer (Inst); Tempest Therapeutics (Inst); Tesaro (Inst) |
Patents, Royalties, Other Intellectual Property - United States Patent Nos 10,258,604 & 10,905,659, licensed by Duke University to Sermonix (Inst) |
| |
|
Employment - Roswell Park Cancer Institute |
Consulting or Advisory Role - MD Anderson Cancer Center |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - GlaxoSmithKline |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - ASCCP |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Eisai; EQRx; Genentech; Genmab; Gilead Sciences; GlaxoSmithKline; GOG Foundation; Lilly; Merck; Nuvation Bio; Onconova Therapeutics; Onconova Therapeutics; Regeneron; Seagen |
| |
|
Honoraria - Alkermes; Symphogen |
Consulting or Advisory Role - Agenus; Allarity Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Curelab Oncology; Eisai; GlaxoSmithKline; GlaxoSmithKline; Immunogen; Lilly; Merck; NextCure; ProfoundBio; Tango Therapeutics |
Speakers' Bureau - Med Learning Group |
Research Funding - Fujifilm; Immunogen; Leap Therapeutics; Merck; Mersana; Novartis; SQZ Biotech; Syndax; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca; Immunogen |